tirzepatide update Mission Family Medicine launches in-clinic program FDA Says Shortage of GLP-1

Do I have to choose between CBD and THC

Both medications can be expensive

The firm acknowledged that releasing OOS compounded preparations reflects a deviation from internal quality assurance procedures and obligation to notify patients and prescribers. But the FDA found that no corrective actions were provided to address the failure to notify patients and prescribers when OOS results were identified

7,21,25 A phenomenon known as inflammaging, chronic low-level inflammation that often accompanies aging, is an important driver of atherosclerosis

$75 for basic bag of fluid

KEY TAKEAWAYS Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes, with demonstrated superior efficacy in glycemic control and weight loss compared to existing treatments